Search results for Eli Lilly and Company - Clinical Trials Registry - ICH GCP

Example: Heart Attack

Clinical Trials Sponsored by Eli Lilly and Company

Total 2472 results

NCT05691712

Recruiting

A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Conditions: Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
NCT05662332

Recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)

Conditions: Type 2 Diabetes, T2D
NCT05592275

Recruiting

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction
NCT05564039

Recruiting

A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Conditions: Type 2 Diabetes
NCT05559359

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Conditions: Atopic Dermatitis, Eczema
NCT05536804

Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Conditions: Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
NCT05514054

Recruiting

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Conditions: Breast Neoplasms
NCT05509790

Recruiting

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Conditions: Breast Neoplasms
NCT05508789

Recruiting

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
NCT05486208

Recruiting

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Conditions: Healthy, Dermatitis, Atopic
NCT05463744

Recruiting

A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

Conditions: Type 1 Diabetes, Diabetes
NCT05440786

Recruiting

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Conditions: Sarcoma, Ewing, Neoplasm Metastasis
NCT05372419

Recruiting

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Conditions: Atopic Dermatitis
NCT05369403

Recruiting

A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Conditions: Atopic Dermatitis
NCT05327595

Recruiting

A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)

Conditions: Diabetes Mellitus, Type 2
NCT05295940

Recruiting

A Study of LY3841136 in Healthy and Overweight Participants

Conditions: Obesity, Healthy
NCT05288166

Recruiting

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Conditions: Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
NCT05169567

Recruiting

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Conditions: Breast Neoplasm, Neoplasm Metastasis
NCT05074420

Recruiting

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)

Conditions: Covid19, Corona Virus Infection
NCT04975308

Recruiting

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Conditions: Breast Neoplasms, Neoplasm Metastasis
NCT04819100

Recruiting

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Carcinoma, Non-Small-Cell Lung
NCT04451408

Recruiting

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

Conditions: Alzheimer Disease, Healthy
NCT04396574

Recruiting

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Conditions: Migraine
NCT04232553

Recruiting

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Conditions: Crohn's Disease
NCT04211337

Recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Conditions: Medullary Thyroid Cancer